Rosuvastatin Counteracts Vessel Arterialisation and Sinusoid Capillarisation, Reduces Tumour Growth, and Prolongs Survival in Murine Hepatocellular Carcinoma
Figure 7
Effects of rosuvastatin on tumour hepatocyte functions. (a) Representative images of Ki67 immunostaining in normal livers (N, ), untreated HCC, and in rosuvastatin-treated HCC livers (/group) at 16 weeks. (b) Quantification of Ki67-positive hepatocytes. Rosuvastatin did not affect the number of Ki67-proliferative hepatocytes in HCC. (c) Proliferation of cultured hepatocytes isolated from HCC livers with or without Rosuvastatin (100 μM). Results, expressed as number of hepatocytes per well, are the mean ± S.D of three experiments performed in quintuplicate. (d) Tumour hepatocyte invasion with and without rosuvastatin treatment (100 μM). Adherent tumour hepatocytes on the lower surface of the insert were counted with Mercator software. Results, expressed as a percentage of nontreated tumour hepatocytes, are the mean ± SD of three experiments performed in duplicate. (e) Rho activation assays in tumour hepatocytes with and without rosuvastatin treatment (100 μM). Results, expressed as absorbance, are the mean ± SD of three experiments performed in duplicate, .
